Global pharmaceutical giant Eli Lilly & Co. is considering a $5.9 billion plant in northeast Houston, a potential economic ...

Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some ...

Pharmaceutical manufacturing giant Eli Lilly and Co. is exploring potential economic incentives for a $5.9B biomanufacturing ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

Pharma giant Eli Lilly’s weight loss drug Mounjaro is priced between Rs. 10,000- ₹15,000 in India making it inaccessible to a ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Eli Lilly and Company discovers ... and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including ...